The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology
Review of earlier studies · 2020
- What was studied
- Animal and in-vitro liver pathology models
- Main finding
- Reviews liver polypeptide complex Ventvil and KEDA/Livagen in experimental fibrosis and hepatitis, with immune and antioxidant outcomes.
Study data at a glance
- Participants or experimental model
- Animal and in-vitro liver pathology models
- Reported results
- Reviews liver polypeptide complex Ventvil and KEDA/Livagen in experimental fibrosis and hepatitis, with immune and antioxidant outcomes.
Study limitations and source details
Study limitations
- Extract and tetrapeptide are separate interventions.
- This is a review of experimental models, not a clinical hepatitis treatment trial.
Source details
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Sources checked
Citation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK. The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology Adv Gerontol 33(1):159-164. PMID 32362099
Related compounds
Ventvil
A peptide mixture extracted from animal liver, studied in liver surgery research and a registered Phase II trial.
Livagen
A synthetic tetrapeptide, Lys–Glu–Asp–Ala (KEDA), studied in liver-cell research.